The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

Thinking about what to do with your Daiichi Sankyo Company shares? If you are watching your stocks closely or hunting for opportunities, you have probably noticed this name keeps popping up on analyst ...

AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo on Monday released high-level results from the TROPION-Breast02 Phase 3 trial. The trial is evaluating Datroway (datopotamab deruxtecan) versus the ...

MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and ...

(RTTNews) - Daiichi Sankyo announced that Ifinatamab deruxtecan has been granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with extensive-stage small cell lung ...

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that the ...

The Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with locally advanced or metastatic ...

On June 1, Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: TROPION-Lung02, TROPION-Lung04, and NeoCOAST-2. These studies ...

Merck & Co. and Daiichi Sankyo have pulled an application seeking accelerated Food and Drug Administration approval of one of the drug candidates in their multibillion-dollar collaboration following ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients live ...